Concessus at CPHI 2025 Frankfurt: A Ground-Floor View of Pharma’s Next Evolution

Another year, another whirlwind of innovation at the world’s largest pharmaceutical gathering. CPHI Frankfurt 2025 did not disappoint, transforming the Messe Frankfurt into a living, breathing snapshot of our industry’s future. For our teams from Concessus, walking the halls was more than just a routine visit; it was a strategic mission to identify the trends, technologies, and partnerships that will define the next chapter in drug development and manufacturing.

The overarching themes were clear: agility, sustainability, and digital integration. Here’s our breakdown of the key takeaways from the epicenter of pharma.

Production Equipment: Smarter, Smaller, and More Connected

The days of monolithic, inflexible production lines are numbered. The buzzword on the show floor was “Modular and Continuous Manufacturing.”

Advanced Continuous Processing: We saw impressive advancements in integrated continuous manufacturing systems for both solid dose and biopharmaceuticals. These systems promise greater efficiency, reduced waste, and enhanced quality control through real-time monitoring.
The Rise of the Digital Twin: Equipment vendors are no longer just selling machinery; they’re selling a digital ecosystem. The integration of AI-driven digital twins allows for virtual commissioning, predictive maintenance, and process optimization without interrupting live production. This is a game-changer for minimizing downtime and accelerating scale-up.
Benchtop to GMP: For our clients in early-stage development, the proliferation of compact, GMP-ready benchtop equipment was notable. These systems allow for robust process development with smaller API quantities, de-risking the transition to commercial scale.

Packaging Solutions: Sustainability is Now a Specification

The packaging pavilion was a hive of activity, driven overwhelmingly by the industry’s urgent push towards environmental responsibility.

Circular Economy in Action: We engaged with multiple suppliers offering mono-material, recyclable blister packs—a significant step forward from multi-laminate alternatives. The conversation has shifted from if we should adopt sustainable packaging to how we can implement it without compromising product integrity.
Smart Packaging Goes Mainstream: NFC tags and QR codes on secondary packaging are becoming standard, moving beyond anti-counterfeiting to enable enhanced patient adherence, supply chain transparency, and direct-to-patient data streams.
Serialization 2.0: With global track-and-trace regulations maturing, the solutions on display are more robust and interoperable. The focus is now on cloud-based aggregation and data management, simplifying compliance across complex international supply chains.

New Products & Ingredients: Beyond the Small Molecule

The ingredient halls showcased a vibrant pipeline, with a noticeable emphasis on advanced therapeutics and enabling technologies.

The mRNA Ecosystem is Maturing: Beyond the COVID-19 spotlight, we observed a mature and expanding ecosystem for mRNA raw materials, including novel lipid nanoparticles (LNPs), cap analogs, and high-purity enzymes. The focus is on scalability and stability.
Semi-Synthetics and Fermentation-Derived APIs: There’s a growing emphasis on sustainable and secure sourcing of complex APIs through advanced fermentation and semi-synthetic pathways, reducing reliance on lengthy chemical synthesis or vulnerable plant-based extraction.
Excipients with Function: New functional excipients designed to enhance bioavailability, enable controlled release, and support the formulation of poorly soluble drugs were prominently featured.

The CDMO Landscape: Strategic Partners in a Volatile World

The CDMO pavilion was larger than ever, reflecting the continued industry shift towards strategic outsourcing. The narrative has evolved from simple capacity provision to true innovation partnerships.

End-to-End Expertise: Leading CDMOs are positioning themselves as one-stop shops, offering integrated services from pre-clinical development through to commercial packaging and logistics. This is particularly valuable for virtual and small-to-mid-sized biotechs.
Specialization is Key: We noted CDMOs carving out distinct niches—some in potent compounds and oncology, others in complex injectables or oral film technologies. This allows sponsors to find partners with deep, specific expertise rather than generalist capabilities.
Resilience and Redundancy: In the wake of recent supply chain shocks, CDMOs are heavily marketing their dual-sourcing strategies, geographically diverse manufacturing networks, and robust quality systems to de-risk client programs.

Spotlight: A Rising Force – Portuguese Pharma

One of the most encouraging aspects of this year’s CPHI was the strong and growing presence of Portuguese pharmaceutical companies. The Portuguese pavilion was a hub of quality and innovation, demonstrating that the country is a serious player on the global stage.

We met with several exhibitors specializing in:

Generic APIs and Finished Dosage Forms: Companies with strong regulatory pedigrees (EMA, FDA) offering competitive and reliable sourcing options.
Natural-Derived Active Ingredients: Leveraging Portugal’s rich biodiversity for innovative botanical extracts and phytopharmaceuticals.
Niche CDMOs: Several Portuguese CDMOs showcased impressive capabilities in technology transfer and the manufacturing of complex solid and liquid oral doses.

The message was clear: Portugal offers a compelling combination of technical expertise, regulatory compliance, and strategic European location.

Conclusion: Building the Connected Future

CPHI 2025 confirmed that our industry is in a period of rapid, technology-driven transformation. For Concessus, the event was invaluable. It provided a clear roadmap of the technologies we need to understand and the partners we need to engage with to best serve our clients.

The future of pharma is not just about a single piece of equipment or a new molecule; it’s about building connected, resilient, and sustainable ecosystems. We’re excited to be a part of it and look forward to integrating these insights into our ongoing projects.

Did you attend CPHI 2025? What were your key takeaways? Connect with us to continue the conversation.